Our research clearly points towards an important role of DDX3 overexpression in cancer. We have already had very positive test results in breast cancer but we are also investigating most specific targets such as “smokers” Lung cancer and advanced Prostate cancer. We have further strengthened our investigations into these targets and now we are working on specific line of highly active “cancer optimised” DDX3 inhibitors.